Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease

Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden and one in Italy). A total of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. kourosh says:

    Great job!
    I hope the Vaccine stop the progression of disease in patients who are already suffering from mild dementia.

Leave a Comment

Your email address will not be published. Required fields are marked *